Design Therapeutics IncDSGN
Price$12.24

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$69.8MTTM through 30 Jun 2026
Free Cash Flow -$55.1MTTM through 30 Jun 2026

Margins

Current

Returns

-32.8%ROE
-30.8%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio17.14x
Net Debt-$219.2Mnet cash position
Cash & Equivalents$12.9M

Quality Metrics

Altman Z-Score34.96
Piotroski F-Score1 / 9
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'24'25
FY2025: $0
Diluted EPS-$1.18TTM
'21'22'23'24'25
FY2025: $-1.22

Dividend

No dividend

Capital Allocation

R&D Spend$58.8M

Segment Performance

No segment data available.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.